<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871767</url>
  </required_header>
  <id_info>
    <org_study_id>D1710C00019</org_study_id>
    <secondary_id>EudraCt No. 2009-009423-10</secondary_id>
    <nct_id>NCT00871767</nct_id>
  </id_info>
  <brief_title>AZD5672 Bioavailability Study in Healthy Male and Female Subjects</brief_title>
  <official_title>An Open-Label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the blood levels achieved with a new formulation of
      AZD5672 to an existing formulation of AZD5672 used in previous studies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of AZD5672 using PK variables AUC ss and C max ss</measure>
    <time_frame>Frequent sampling occasions during study periods, with intensive sampling occurring on days 7,14,21 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, safety lab)</measure>
    <time_frame>AE assessed throughout whole the study, twice weekly assessment of BP, pulse and safety labs throughout study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 or 100mg AZD5672, Reference formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 or 100mg AZD5672, Test formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>40 mg tablet (Test formulation)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>40 mg tablet (Reference formulation)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>100 mg tablet (Test formulation)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>100 mg (2 x 50 mg tablet (Reference Formulation)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study-specific procedures

          -  BMI between 18 and 30 kg/m2

          -  Medical and surgical history and physical examination without any clinically
             significant findings

          -  Non smokers or past smokers who have stopped smoking within the last 6 months.

        Exclusion Criteria:

          -  History of clinically significant cardio- or cerebrovascular, pulmonary, renal,
             hepatic, neurological, mental or gastrointestinal disorder or any other major disorder
             that may interfere with the objectives of the study, as judged by the Investigator

          -  Clinically significant illness as judged by the Investigator, within two weeks before
             the first administration of investigational product.

          -  Female subjects who have a positive pregnancy test or who are pregnant or
             breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D, Alderley Park, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Constable</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Layton, MD, PhD, Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>AZD5672</keyword>
  <keyword>relative bioavailability</keyword>
  <keyword>rheumatoid arthritis (RA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

